Medpace Faces Class Action for Securities Fraud
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 55 minutes ago
0mins
Should l Buy MEDP?
Source: Globenewswire
- Lawsuit Background: Leading securities law firm Bleichmar Fonti & Auld LLP has filed a class action lawsuit against Medpace Holdings Inc. and certain executives, alleging securities fraud due to intentional understatements of cancellation rates and overstatements of the book-to-bill ratio, resulting in a 15.9% stock drop on February 9, 2026.
- Stock Price Volatility: On February 9, 2026, Medpace's stock plummeted from $530.35 to $446.05 per share, reflecting severe investor concerns regarding the company's financial health and negatively impacting market expectations for future performance.
- Misleading Financial Data: Medpace claimed a decrease in cancellation rates in its Q4 2025 report, but the reality was an increase in cancellations, leading to a decline in the book-to-bill ratio to 1.04, which further dropped to 0.88 in Q1 2026, indicating underlying operational risks.
- Executive Changes: Amid ongoing stock declines, Medpace's President Jesse Geiger announced his resignation, potentially exacerbating market unease regarding the company's governance and future development.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MEDP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MEDP
Wall Street analysts forecast MEDP stock price to rise
7 Analyst Rating
1 Buy
4 Hold
2 Sell
Hold
Current: 426.790
Low
462.00
Averages
569.17
High
660.00
Current: 426.790
Low
462.00
Averages
569.17
High
660.00
About MEDP
Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Medpace Faces Class Action for Securities Fraud
- Lawsuit Background: Leading securities law firm Bleichmar Fonti & Auld LLP has filed a class action lawsuit against Medpace Holdings Inc. and certain executives, alleging securities fraud due to intentional understatements of cancellation rates and overstatements of the book-to-bill ratio, resulting in a 15.9% stock drop on February 9, 2026.
- Stock Price Volatility: On February 9, 2026, Medpace's stock plummeted from $530.35 to $446.05 per share, reflecting severe investor concerns regarding the company's financial health and negatively impacting market expectations for future performance.
- Misleading Financial Data: Medpace claimed a decrease in cancellation rates in its Q4 2025 report, but the reality was an increase in cancellations, leading to a decline in the book-to-bill ratio to 1.04, which further dropped to 0.88 in Q1 2026, indicating underlying operational risks.
- Executive Changes: Amid ongoing stock declines, Medpace's President Jesse Geiger announced his resignation, potentially exacerbating market unease regarding the company's governance and future development.
See More
Reminder for Medpace Stock Class Action Lawsuit
- Class Action Notice: Rosen Law Firm reminds investors who purchased Medpace Holdings, Inc. (NASDAQ:MEDP) common stock between April 22, 2025, and February 9, 2026, to apply as lead plaintiffs by June 8, 2026, to participate in the class action lawsuit and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages more affected investors to participate.
- Lawsuit Background: The lawsuit alleges that Medpace made false or misleading statements during the class period, concealing its true backlog cancellation rates, which led to overly optimistic growth expectations among investors, ultimately resulting in financial losses.
- Law Firm Expertise: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its expertise and success rate in this field, prompting investors to carefully select experienced legal counsel.
See More
Medpace Faces Class Action Lawsuit Allegations
- Class Action Initiation: Robbins Geller law firm announces that investors who purchased Medpace Holdings Inc. (NASDAQ:MEDP) common stock between April 22, 2025, and February 9, 2026, have until June 8, 2026, to seek lead plaintiff status in the class action lawsuit, indicating significant investor concern over potential financial losses.
- False Statement Allegations: The lawsuit alleges that Medpace and its executives made false and misleading statements during the class period, particularly regarding the projected book-to-bill ratio for Q4 2025, leading to investor misjudgment of the company's performance and potentially triggering broader legal and financial repercussions.
- Performance Decline Impact: On February 9, 2026, Medpace reported a book-to-bill ratio of 1.04 for Q4 2025, significantly below the prior guidance of 1.15, resulting in a nearly 16% drop in stock price, reflecting a severe erosion of market confidence in the company's outlook.
- Legal Process Explanation: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Medpace stock during the class period can apply to be the lead plaintiff, who will represent other investors in the lawsuit, potentially influencing future recovery outcomes.
See More
Reminder for Medpace Investors on Class Action Deadline
- Lawsuit Background: Glancy Prongay Wolke & Rotter LLP reminds investors of the June 8, 2026 deadline to file a lead plaintiff motion in a class action for those who purchased Medpace stock between April 22, 2025, and February 9, 2026, aiming to recover losses due to the company's poor performance.
- Financial Miss: On February 9, 2026, Medpace reported a book-to-bill ratio of 1.04 for Q4 2025, significantly below the expected 1.15, primarily due to a record high in order cancellations, resulting in a 15.9% drop in stock price to $446.05 per share the following day.
- False Statement Allegations: The lawsuit alleges that throughout the class period, the company made materially false and misleading statements, failing to disclose adverse facts affecting its business and prospects, particularly regarding the overly optimistic projections of the book-to-bill ratio and disregard for cancellations.
- Investor Impact: As a result of the company's failure to accurately reflect its business conditions, investors face significant financial losses, and the outcome of the lawsuit could impact the company's future reputation and shareholder trust, exacerbating market concerns over its financial transparency.
See More
Investor Class Action Lawsuit Reminder
- Gossamer Bio Lawsuit: Gossamer Bio (NASDAQ:GOSS) faces a class action lawsuit for the period from June 16, 2025, to February 20, 2026, due to failure to disclose critical patient data, resulting in its Phase 3 PROSERA study not meeting primary endpoints, with a lead plaintiff deadline of June 1, 2026.
- New Era Energy Issues: New Era Energy (NASDAQ:NUAI) is involved in a class action lawsuit for the period from November 6, 2024, to December 29, 2025, for overstating progress on its Texas data center project and engaging in fraudulent schemes, with a deadline for lead plaintiffs also set for June 1, 2026.
- Medpace Holdings Allegations: Medpace Holdings (NASDAQ:MEDP) is facing a class action lawsuit for the period from April 22, 2025, to February 9, 2026, due to misleading statements regarding its projected book-to-bill ratio, with a lead plaintiff deadline of June 5, 2026.
- Legal Consultation Advice: Investors who have suffered losses in these companies are encouraged to contact The Law Offices of Frank R. Cruz to understand their legal rights and remain vigilant regarding the class actions to ensure necessary actions are taken before the deadlines.
See More
Medpace Faces Securities Class Action Lawsuit
- Significant Stock Drop: Medpace's shares fell by $84.30, a decline of over 15.9%, following the disclosure of its fourth-quarter 2025 results, indicating serious issues with the company's financial transparency that could undermine investor confidence.
- False Statement Allegations: The lawsuit alleges that Medpace's management provided misleading projections regarding the book-to-bill ratio, claiming it would be 1.15 for the second half of 2025, while the actual figure was 1.04, leading investors to purchase shares at artificially inflated prices and incur substantial losses.
- Investor Responsibility Assessment: Institutional investors who acquired MEDP shares between April 22, 2025, and February 9, 2026, must evaluate their fiduciary obligations and consider participating in the class action lawsuit to seek compensation, reflecting a commitment to protecting investor rights.
- Importance of Class Action: As lead plaintiffs in the class action, institutional investors play a critical role in ensuring effective oversight of corporate management, driving accountability for alleged disclosure failures, and highlighting the essential role of institutional investors in maintaining market integrity.
See More
Medpace Faces Class Action for Securities Fraud
- Lawsuit Background: Leading securities law firm Bleichmar Fonti & Auld LLP has filed a class action lawsuit against Medpace Holdings Inc. and certain executives, alleging securities fraud due to intentional understatements of cancellation rates and overstatements of the book-to-bill ratio, resulting in a 15.9% stock drop on February 9, 2026.
- Stock Price Volatility: On February 9, 2026, Medpace's stock plummeted from $530.35 to $446.05 per share, reflecting severe investor concerns regarding the company's financial health and negatively impacting market expectations for future performance.
- Misleading Financial Data: Medpace claimed a decrease in cancellation rates in its Q4 2025 report, but the reality was an increase in cancellations, leading to a decline in the book-to-bill ratio to 1.04, which further dropped to 0.88 in Q1 2026, indicating underlying operational risks.
- Executive Changes: Amid ongoing stock declines, Medpace's President Jesse Geiger announced his resignation, potentially exacerbating market unease regarding the company's governance and future development.
See More
Reminder for Medpace Stock Class Action Lawsuit
- Class Action Notice: Rosen Law Firm reminds investors who purchased Medpace Holdings, Inc. (NASDAQ:MEDP) common stock between April 22, 2025, and February 9, 2026, to apply as lead plaintiffs by June 8, 2026, to participate in the class action lawsuit and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages more affected investors to participate.
- Lawsuit Background: The lawsuit alleges that Medpace made false or misleading statements during the class period, concealing its true backlog cancellation rates, which led to overly optimistic growth expectations among investors, ultimately resulting in financial losses.
- Law Firm Expertise: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its expertise and success rate in this field, prompting investors to carefully select experienced legal counsel.
See More
Medpace Faces Class Action Lawsuit Allegations
- Class Action Initiation: Robbins Geller law firm announces that investors who purchased Medpace Holdings Inc. (NASDAQ:MEDP) common stock between April 22, 2025, and February 9, 2026, have until June 8, 2026, to seek lead plaintiff status in the class action lawsuit, indicating significant investor concern over potential financial losses.
- False Statement Allegations: The lawsuit alleges that Medpace and its executives made false and misleading statements during the class period, particularly regarding the projected book-to-bill ratio for Q4 2025, leading to investor misjudgment of the company's performance and potentially triggering broader legal and financial repercussions.
- Performance Decline Impact: On February 9, 2026, Medpace reported a book-to-bill ratio of 1.04 for Q4 2025, significantly below the prior guidance of 1.15, resulting in a nearly 16% drop in stock price, reflecting a severe erosion of market confidence in the company's outlook.
- Legal Process Explanation: Under the Private Securities Litigation Reform Act of 1995, any investor who purchased Medpace stock during the class period can apply to be the lead plaintiff, who will represent other investors in the lawsuit, potentially influencing future recovery outcomes.
See More
Reminder for Medpace Investors on Class Action Deadline
- Lawsuit Background: Glancy Prongay Wolke & Rotter LLP reminds investors of the June 8, 2026 deadline to file a lead plaintiff motion in a class action for those who purchased Medpace stock between April 22, 2025, and February 9, 2026, aiming to recover losses due to the company's poor performance.
- Financial Miss: On February 9, 2026, Medpace reported a book-to-bill ratio of 1.04 for Q4 2025, significantly below the expected 1.15, primarily due to a record high in order cancellations, resulting in a 15.9% drop in stock price to $446.05 per share the following day.
- False Statement Allegations: The lawsuit alleges that throughout the class period, the company made materially false and misleading statements, failing to disclose adverse facts affecting its business and prospects, particularly regarding the overly optimistic projections of the book-to-bill ratio and disregard for cancellations.
- Investor Impact: As a result of the company's failure to accurately reflect its business conditions, investors face significant financial losses, and the outcome of the lawsuit could impact the company's future reputation and shareholder trust, exacerbating market concerns over its financial transparency.
See More
Investor Class Action Lawsuit Reminder
- Gossamer Bio Lawsuit: Gossamer Bio (NASDAQ:GOSS) faces a class action lawsuit for the period from June 16, 2025, to February 20, 2026, due to failure to disclose critical patient data, resulting in its Phase 3 PROSERA study not meeting primary endpoints, with a lead plaintiff deadline of June 1, 2026.
- New Era Energy Issues: New Era Energy (NASDAQ:NUAI) is involved in a class action lawsuit for the period from November 6, 2024, to December 29, 2025, for overstating progress on its Texas data center project and engaging in fraudulent schemes, with a deadline for lead plaintiffs also set for June 1, 2026.
- Medpace Holdings Allegations: Medpace Holdings (NASDAQ:MEDP) is facing a class action lawsuit for the period from April 22, 2025, to February 9, 2026, due to misleading statements regarding its projected book-to-bill ratio, with a lead plaintiff deadline of June 5, 2026.
- Legal Consultation Advice: Investors who have suffered losses in these companies are encouraged to contact The Law Offices of Frank R. Cruz to understand their legal rights and remain vigilant regarding the class actions to ensure necessary actions are taken before the deadlines.
See More
Medpace Faces Securities Class Action Lawsuit
- Significant Stock Drop: Medpace's shares fell by $84.30, a decline of over 15.9%, following the disclosure of its fourth-quarter 2025 results, indicating serious issues with the company's financial transparency that could undermine investor confidence.
- False Statement Allegations: The lawsuit alleges that Medpace's management provided misleading projections regarding the book-to-bill ratio, claiming it would be 1.15 for the second half of 2025, while the actual figure was 1.04, leading investors to purchase shares at artificially inflated prices and incur substantial losses.
- Investor Responsibility Assessment: Institutional investors who acquired MEDP shares between April 22, 2025, and February 9, 2026, must evaluate their fiduciary obligations and consider participating in the class action lawsuit to seek compensation, reflecting a commitment to protecting investor rights.
- Importance of Class Action: As lead plaintiffs in the class action, institutional investors play a critical role in ensuring effective oversight of corporate management, driving accountability for alleged disclosure failures, and highlighting the essential role of institutional investors in maintaining market integrity.
See More
